// App-Quantinova.ai

4030 : Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI- AGEO).

Researchers

Presenter

  • Simon Pernot

Principal Investigators

  • Magali Terme

  • Florence Castan

  • Elie Marcheteau

  • Olivier Bouche

  • Jaafar Bennouna

  • Eric Francois

  • Francois Ghiringhelli

  • Christelle De La Fouchardiere

  • Emmanuelle Samalin

  • Jean Baptiste Bachet

  • Christophe Borg

  • Michel Ducreux

  • Aurelie Cazes

  • Trevor Stanbury

  • Sophie Gourgou

  • David Malka

  • Julien Taieb

Medical Centers

  • Hopital European Georges Pompidou, Paris, France

  • Department of Pathology, Hopital Europeen Georges Pompidou, APHP - Paris Descartes University, Paris, France

  • INSERM U970- Paris-Descartes University, Paris, France

  • Biometrics Department, Institut du Cancer Montpellier, Montpellier, France

  • INSERM U970- Paris-Descartes University, Paris, France

  • CHU Robert Debre, Reims, France

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Centre Antoine-Lacassagne, Nice, France

  • Center Georges-Francois Leclerc, Dijon, France

  • Centre Leon Berard, Lyon, France

  • CRLC Val d'Aurelle, Montpellier, France

  • Salpetriere Hospital, Paris, France

  • Medical Oncology Unit, CHU Minjoz, Besancon, France

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Hopital European Georges Pompidou, Paris, France

  • UNICANCER, Paris, France

  • Biostatistic Unit - CTD INCa, ICM - Montpellier Cancer Institute, Montpellier, France

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • panitumumab

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01443065

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved